Head and Neck Squamous Cell Carcinoma
Conditions
Brief summary
A phase II study to evaluate the efficacy and safety of Docetaxel-PM in recurrent or metastatic head and neck squamous cell carcinoma
Interventions
DRUGDocetaxel-PM
Docetaxel PM 75mg/m2 IV infusion
Sponsors
Samyang Biopharmaceuticals Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
1. Patients who were histologically or cytologically diagnosed as having oral cavity, oropharynx, hypopharynx, or larynx squamous cell carcinoma with recurrent and metastatic evidence and who cannot be treated by salvage surgery or radiotherapy 2. Time of disease progression, regardless of whether that treatment or after platinum-based therapy ①Patients who have disease progression after concurrent chemoradiotherapy of curative purpose (including induction chemotherapy) including a platinum-based (cisplatin or carboplatin) chemotherapy ② Patients who have disease progression after primary or secondary treatment of palliative purpose including a platinum-based (cisplatin or carboplatin) chemotherapy 3. Patients who aged 20 years or older and under 79 years old 4. Patients whose Eastern Cooperative Oncology Group (ECOG) performance scores are 0-2 5. Patients who have one measurable lesion at least by RECIST criteria 1.1 6. Patients who show adequate function of organ: * bone marrow: Absolute Neutrophil count (ANC) ≥ 1,500/μL, Platelet count ≥ 100,000/μ, Hb≥ 9.0 g/dl (allowed blood transfusion) * Liver: ① with no evidence of liver metastasis; Total bilirubin ≤ 1.5mg/dl, alkaline phosphatase (ALP), aspartate transaminase (AST), alanine transaminase (ALT) ≤ 2.0 X upper limit of normal (ULN) ② with liver metastasis; bilirubin ≤ 3.0 X ULN, aspartate transaminase (AST), alanine transaminase (ALT) ≤ 5.0 X ULN * Kidney: creatinine ≤ 1.5 X ULN 7. Patients who have signed written consent forms prior to participation in the clinical trial
Exclusion criteria
1. Patients who have Primary tumor of nasopharynx 2. Patients who have received treatment prior regimen of three or more drugs 3. Patients who have Primary malignant tumors of other sites (except if; early cervical cancer, skin basal cell cancer received appropriate treatment, Malignant tumor without recurrent state treated five years previously) 4. Previous radiotherapy is allowed, patients who should be completed radiotherapy before 4 weeks prior to the initial administration of the investigational product 5. Patients who have received a major surgery within 4 weeks prior to the initial administration of the investigational product or patients who does not recover after major surgery 6. Patients who have severe diseases or medical condition as follows * Congestive heart failure(NYHA class III or IV) * Unstable angina, cardiac infarction within 6 months * Second-degree atrioventricular (AV) block or more, clinically cardiac arrhythmia that needs drug therapy * Uncontrollable Hypertension * Hepatic cirrhosis (≥ Child class B) * Interstitial lung disease * Mental disorder not to comply with the protocol * Uncontrolled diabetes * Uncontrolled ascites or pulmonary edema * Active infection 7. Pregnant or lactating women 8. Patients considered inappropriate to participating the study by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response rate as assessed by RECIST v1.1 | 2 years | Response is confirmed at least 4 weeks later. Assessment: every 6 weeks (treatment period), every 2 months (follow-up period) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | 2 years | Assessment: every 2 months (follow-up period) |
| Disease control rate (DCR) | 2 years | DCR is defined as the percentage of patients who have achieved complete response, partial response and stable disease |
| Overall survival | 2 years | Assessment: every 2 months (follow-up period) |
| Number of participants with adverse events as assessed by CTCAE v4.0 | 2 years | — |
| Incidence rate of hypersensitivity reaction to Docetaxel-PM | 2 years | — |
Countries
South Korea
Outcome results
None listed